Cited by 248Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorForensic Toxicology and Drug Analysis

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans

Liechti, M·2000·Neuropsychopharmacology

DOI 10.1016/s0893-133x(00)00126-3

Open this paper in CoChat — free account

Abstract

MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") mainly releases serotonin and dopamine. In animals, pretreatment with 5-HT(2) antagonists has been shown to attenuate neurochemical and behavioral effects of MDMA. In humans, the role of 5-HT(2) receptors in the action of MDMA has not been studied. We investigated the effect of pretreatment with the 5-HT(2A/C) antagonist ketanserin (50 mg p.o.) on subjective responses to MDMA (1.5 mg/kg p.o.) in 14 healthy volunteers using a double-blind placebo-controlled within-subject design. Subjective effects were rated by psychometric rating scales. Physiological effects measured were blood pressure, heart rate, and body temperature. Adverse effects were assessed during the sessions, and after one and three days. Ketanserin attenuated MDMA-induced perceptual changes, emotional excitation, and acute adverse responses but had little effect on MDMA-induced positive mood, well-being, extroversion, and short-term sequelae. Body temperature was lower under MDMA plus ketanserin compared to MDMA alone. The results suggest a contributing role for 5-HT(2) receptors in the action of MDMA in humans.

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(00)00126-3

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

STAI manual for the State-trait anxiety inventory
Cd, S. (1970) · Medical Entomology and Zoology · Cited by 2,433
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
Leysen, J. E., Awouters, F. H. L., Kennis, L. E. J., Laduron, P. M., Vandenberk, J., & Janssen, P. A. J. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90747-5 · Cited by 843
Relationship between subjective effects of cocaine and dopamine transporter occupancy
Volkow, N. D., Wang, G., Fischman, M. W., Foltin, R. W., Fowler, J. S., Abumrad, N. N., Vitkun, S. A., Logan, J., Gatley, S. J., Pappas, N. R., et al. (1997) · Nature · doi:10.1038/386827a0 · Cited by 657
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
Rudnick, G., & Wall, S. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1817 · Cited by 535
Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Self-citation
Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans
Mas, M., Farré, M., de la Torre, R., Roset, P. N., Segura, J. O., & Camí, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34877-3 · Cited by 362
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
Titeler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343

Show all 34 references

Sorted by citations

Items 101–200 of 248

Initial deficit and recovery of function after MDMA preexposure in rats
Brennan, K. A., & Schenk, S. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0278-y · Cited by 35
Ecstasy produces left ventricular dysfunction and oxidative stress in rats
Shenouda, S. K., Lord, K. C., McIlwain, E., Lucchesi, P. A., & Varner, K. J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn129 · Cited by 35
Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature
Uys, J. D. K., & Niesink, R. J. M. (2005) · Drug and Alcohol Review · doi:10.1080/09595230500295725 · Cited by 34
Discriminative Stimulus Effects of Psychostimulants and Hallucinogens in S(+)-3,4-Methylenedioxymethamphetamine (MDMA) and R(−)-MDMA Trained Mice
Murnane, K. S., Murai, N., Howell, L. L., & Fantegrossi, W. E. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156174 · Cited by 34
Somatostatin interneurons activated by 5-HT2A receptor suppress slow oscillations in medial entorhinal cortex
Filippo, R. D., Rost, B. R., Stumpf, A., Cooper, C., Tukker, J. J., Harms, C., Beed, P. S., & Schmitz, D. (2021) · eLife · doi:10.7554/elife.66960 · Cited by 34
Acute medical problems due to Ecstasy use
Kunz, I. (2005) · Swiss Medical Weekly · doi:10.4414/smw.2005.11231 · Cited by 65
Identification and quantitation of 3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy) in human urine by 1H NMR spectroscopy. Application to five cases of intoxication
Liu, J., Decatur, J. D., Proni, G., & Champeil, É. (2009) · Forensic Science International · doi:10.1016/j.forsciint.2009.10.022 · Cited by 32
MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
Puxty, D. J., Ramaekers, J. G., de la Torre, R., Farré, M., Pizarro, N., Pujadas, M., & Kuypers, K. P. C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00455 · Cited by 32
MDMA for the Treatment of Negative Symptoms in Schizophrenia
Arnovitz, M. D., Spitzberg, A. J., Davani, A. J., Vadhan, N. P., Holland, J. A., Kane, J. M., & Michaels, T. I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123255 · Cited by 31
The Altered States Database: Psychometric data from a systematic literature review
Prugger, J., Derdiyok, E., Dinkelacker, J., Costines, C., & Schmidt, T. T. (2022) · Scientific Data · doi:10.1038/s41597-022-01822-4 · Cited by 36
Unique effects of sedatives, dissociatives, psychedelics, stimulants, and cannabinoids on episodic memory: A review and reanalysis of acute drug effects on recollection, familiarity, and metamemory.
Doss, M. K., Samaha, J., Barrett, F. S., Griffiths, R. R., de Wit, H., Gallo, D. A., & Koen, J. D. (2023) · Psychological Review · doi:10.1037/rev0000455 · Cited by 33
Effects of ecstasy on cooperative behaviour and perception of trustworthiness: A naturalistic study
Stewart, L. H., Ferguson, B., Morgan, C. J. A., Swaboda, N., Jones, L., Fenton, R., Wall, M. B., & Curran, H. V. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114544775 · Cited by 32
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine
Avram, M., Fortea, L., Wollner, L., Coenen, R., Korda, A. I., Rogg, H. V., Holze, F., Vizeli, P., Ley, L., Raduà, J., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02734-y · Cited by 32
Self-citation
Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction
Sala, M., & Braida, D. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.016 · Cited by 29
Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics
Mason, N. L., & Kuypers, K. P. C. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.006 · Cited by 28
An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users
Pirona, A., & Morgan, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102780 · Cited by 27
A novel MDMA analogue, UWA‐101, that lacks psychoactivity and cytotoxicity, enhances l ‐DOPA benefit in parkinsonian primates
Johnston, T. H., Millar, Z. A., Huot, P., Wagg, K., Thiele, S. L., Salomonczyk, D., Yong-Kee, C. J., Gandy, M. N., McIldowie, M. J., Lewis, K. D., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-195016 · Cited by 27
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 27
Serotonin and Serotonin Receptors in Hallucinogen Action
Halberstadt, A. L., & Nichols, D. E. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70103-x · Cited by 26
The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder
Amoroso, T. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1094156 · Cited by 28
MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor
Kuypers, K. P. C., de la Torre, R., Farré, M., Pizarro, N., Xicota, L., & Ramaekers, J. G. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4699-1 · Cited by 26
MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task
Vollenweider, F. X., Liechti, M. E., & Paulus, M. P. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105053287 · Cited by 24
Self-citation
New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine
Chaudhary, S., Ponnala, S., LeGendre, O., Gonzales, J., Navarro, H. A., & Harding, W. W. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.019 · Cited by 23
MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice
Young, R. C., & Glennon, R. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.09.002 · Cited by 22
Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and mechanisms
Fonseca, D. A., Ribeiro, D. M., Tapadas, M., & Cotrim, M. D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174156 · Cited by 24
Treatment Recommendations for Psychedelic-assisted Therapy
Aicher, H., & Gasser, P. (2024) · Swiss Archives of Neurology Psychiatry and Psychotherapy · doi:10.4414/sanp.2024.1488043038 · Cited by 21
Experience-dependent changes in temperature and behavioral activity induced by MDMA
Reveron, M. E., Maier, E. Y., & Duvauchelle, C. L. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.06.021 · Cited by 21
PRECLINICAL STUDY: FULL ARTICLE: Tolerance to 3,4‐methylenedioxymethamphetamine is associated with impaired serotonin release
Jones, K. L., Brennan, K. A., Colussi‐Mas, J., & Schenk, S. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00217.x · Cited by 20
Serotonin antagonists fail to alter MDMA self-administration in rats
Schenk, S., Foote, J., Aronsen, D., Bukholt, N., Highgate, Q., van de Wetering, R., & Webster, J. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.06.002 · Cited by 16
Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain
Bull, E., Porkess, V., Rigby, M., Hutson, P. H., & Fone, K. C. F. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059583 · Cited by 18
Pizotyline effectively attenuates the stimulus effects of N-Methyl-3,4-methylenedioxyamphetamine (MDMA)
Young, R., Khorana, N., Bondareva, T. S., & Glennon, R. A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.09.010 · Cited by 20
3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner
Pitts, E. G., Minerva, A. R., Chandler, E. B., Kohn, J. N., Logun, M. T., Sulima, A., Rice, K. C., & Howell, L. L. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.80 · Cited by 20
Key interindividual determinants in MDMA pharmacodynamics
Papaseit, E., Torrens, M., Pérez‐Mañá, C., Muga, R., & Farré, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1424832 · Cited by 20
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 24
MDMA and the Brain: A Short Review on the Role of Neurotransmitters in the Cause of Neurotoxicity
Mustafa, N. S., & Mohamad, N. (2019) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.9.10.485 · Cited by 19
MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P., & Kvamme, T. L. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110843 · Cited by 21
Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis
Basedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 19
Male and female ecstasy users: Differences in patterns of use, sleep quality and mental health outcomes
Ogeil, R. P., Rajaratnam, S. M. W., & Broadbear, J. H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.02.002 · Cited by 20
Synthetic studies and pharmacological evaluations on the MDMA (‘Ecstasy’) antagonist nantenine
LeGendre, O., Pecic, S., Chaudhary, S., Zimmerman, S. M., Fantegrossi, W. E., & Harding, W. W. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.053 · Cited by 19
Daphnia magna an emerging environmental model of neuro and cardiotoxicity of illicit drugs.
Bellot, M., Soria, F., López‐Arnau, R., Gómez‐Canela, C., & Barata, C. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123355 · Cited by 28
Sympathomimetic amine compounds and hepatotoxicity: Not all are alike—Key distinctions noted in a short review
Willson, C. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.11.013 · Cited by 18
Involvement of 5‐HT2A Receptors in the Serotonin (5‐HT) Syndrome caused by Excessive 5‐HT Efflux in Rat Brain
Krishnamoorthy, S., Ma, Z., Zhang, G., Wei, J., Auerbach, S. B., & Tao, R. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00586.x · Cited by 18
Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’)
Aguilar, M. A., García-Pardo, M. P., & Parrott, A. C. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146556 · Cited by 18
Disruption of prepulse inhibition by 3,4-methylenedioxymethamphetamine (MDMA): comparison between male and female wild-type and 5-HT1A receptor knockout mice
van den Buuse, M., Becker, T., Kwek, P., Martin, S., Ruimschotel, E., & Risbrough, V. B. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000101 · Cited by 17
POTENTIATION OF 3,4‐METHYLENEDIOXYMETHAMPHETAMINE‐INDUCED 5‐HT RELEASE IN THE RAT SUBSTANTIA NIGRA BY CLORGYLINE, A MONOAMINE OXIDASE A INHIBITOR
Hewton, R., Salem, A., & Irvine, R. J. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04734.x · Cited by 17
Couple Therapy With MDMA—Proposed Pathways of Action
Wagner, A. C. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.733456 · Cited by 16
Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration
Avram, M., Müller, F., Preller, K. H., Razi, A., Rogg, H. V., Korda, A. I., Holze, F., Vizeli, P., Ley, L., Liechti, M. E., et al. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.07.010 · Cited by 17
Self-citation
3,4‐Methylenedioxymethamphetamine (MDMA) enhances the release of acetylcholine by 5‐HT4and D1receptor mechanisms in the rat prefrontal cortex
Nair, S. G., & Gudelsky, G. A. (2005) · Synapse · doi:10.1002/syn.20202 · Cited by 15
Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake
Yubero‐Lahoz, S., Kuypers, K. P. C., Ramaekers, J. G., Langohr, K., Farré, M., & de la Torre, R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3827-4 · Cited by 14
Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls
Carhart-Harris, R. L., Nutt, D., Munafo, M. R., Christmas, D. M., & Wilson, S. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1595-3 · Cited by 14
PRECLINICAL STUDY: Atypical development of behavioural sensitization to 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in adolescent rats and its expression in adulthood: role of the MDMA chirality
Ameln, N. V., & von Ameln-Mayerhofer, A. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00187.x · Cited by 14
„Ecstasy” (MDMA): Pharmakologie, Toxikologie und Behandlung der akuten Intoxikation
Liechti, M. E. (2003) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2003-39975 · Cited by 14
Self-citation
Role of Serotonin Transporter and Receptor Gene Variations in the Acute Effects of MDMA in Healthy Subjects
Vizeli, P., zu Schwabedissen, H. E. M., & Liechti, M. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00590 · Cited by 13
Self-citation
The Role of Serotonin in Drug Addiction
Müller, C. P., Pum, M. E., Schumann, G., & Huston, J. P. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70099-0 · Cited by 13
Pharmacological characterization of the aminorex analogs 4-MAR, 4,4′-DMAR, and 3,4-DMAR
Rickli, A., Kolaczynska, K. E., Hoener, M. C., & Liechti, M. E. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.02.011 · Cited by 13
Self-citation
Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”
Kvam, T.-M., Goksøyr, I. W., Stewart, L. H., Repantis, D., Røssberg, J. I., & Andreassen, O. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.954388 · Cited by 12
The arginine-vasotocin and serotonergic systems affect interspecific social behaviour of client fish in marine cleaning mutualism
Triki, Z., Bshary, R., Grutter, A. S., & Ros, A. F. H. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.011 · Cited by 10
Methodological problems with ecstasy and the SCL-90
Cole, J. C., Sumnall, H. R., & Wagstaff, G. F. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1108-0 · Cited by 11
Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
Kaur, H., Karabulut, S., Gauld, J. W., Fagot, S. A., Holloway, K. N., Shaw, H. E., & Fantegrossi, W. E. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0023 · Cited by 10
Effects of chronic intracerebroventricular 3,4-methylenedioxy-N-methamphetamine (MDMA) or fluoxetine on the active avoidance test in rats with or without exposure to mild chronic stress
León, L. A., Landeira-Fernández, J., & Cárdenas, F. P. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.039 · Cited by 10
Synthesis of 3-(Pyridin-2-yl)quinazolin-2,4(1H,3H)-diones via Annulation of Anthranilic Esters with N-pyridyl Ureas
Baykova, S. O., Geyl, K. K., Baykov, S. V., & Boyarskiy, V. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087633 · Cited by 10
Successful treatment of intractable visual hallucinations with 5-HT2Aantagonist ketanserin
Sommer, I. E., Kleijer, H., Visser, L., & van Laar, T. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224340 · Cited by 10
Inhibition of the dorsomedial hypothalamus, but not the medullary raphe pallidus, decreases hyperthermia and mortality from MDMA given in a warm environment
Zaretsky, D. V., Zaretskaia, M. V., Durant, P. J., & Rusyniak, D. E. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.31 · Cited by 9
Mirtazapine and ketanserin alter preference for gambling-like schedules of reinforcement in rats
Persons, A. L., Tedford, S. E., & Celeste, T. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.027 · Cited by 9
Ecstasy and sleep disturbance: Progress towards elucidating a role for the circadian system
Ogeil, R. P., Rajaratnam, S. M. W., & Broadbear, J. H. (2011) · Sleep and Biological Rhythms · doi:10.1111/j.1479-8425.2011.00510.x · Cited by 10
Neurochemical substrates of the rewarding effects of MDMA
Roger-Sánchez, C., García-Pardo, M. P., Rodríguez‐Arias, M., Miñarro, J., & Aguilar, M. A. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000210 · Cited by 9
Safety pharmacology of acute mescaline administration in healthy participants
Klaiber, A., Humbert‐Droz, M., Ley, L., Schmid, Y., & Liechti, M. E. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16349 · Cited by 8
Self-citation
The effect of self-compassion training on craving and self-efficacy in female patients with methamphetamine dependence: a one-year follow-up
Abdoli, N., Farnia, V., Radmehr, F., Alikhani, M., Moradinazar, M., Khodamoradi, M., Salemi, S., Rezaei, M., & Davarinejad, O. (2020) · Journal of Substance Use · doi:10.1080/14659891.2020.1851406 · Cited by 8
Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users
Soar, K., Parrott, A., & Turner, J. J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108092594 · Cited by 8
The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs
Mori, T., & Suzuki, T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_29 · Cited by 8
Monoamine Transporter and Receptor Interaction Profiles of Synthetic Cathinones
Simmler, L. D. (2018) · Current topics in neurotoxicity · doi:10.1007/978-3-319-78707-7_6 · Cited by 8
No effect of MDMA (ecstasy) on cell death and 5-HT2A receptor density in organotypic rat hippocampal cultures
Sveen, M., Knudsen, G. M., & Aznar, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.01.051 · Cited by 8
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
Kvam, T.-M., Goksøyr, I. W., Rog, J., van de Vooren, I.-T. J., Stewart, L. H., Autran, I., Berthold‐Losleben, M., Mørch-Johnsen, L. E., Holst, R., Clausen, I., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.10320 · Cited by 9
A Systematic Review of the MDMA Model to Address Social Impairment in Autism
Chaliha, D. R., Mamo, J. C. L., Albrecht, M. A., Lam, V., Takechi, R., & Vaccarezza, M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210101130258 · Cited by 7
Psychedelic Therapy: A Primer for Primary Care Clinicians—3,4-Methylenedioxy-methamphetamine (MDMA)
Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001722 · Cited by 9
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Studerus, E. (2012) · University of Zurich · doi:10.5167/uzh-164092 · Cited by 6
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns
Baldo, B. A. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03765-8 · Cited by 6
Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation
Puerta, E., & Aguirre, N. (2011) · Pharmaceuticals · doi:10.3390/ph4070992 · Cited by 6
Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats
Halberstadt, A. L., Buell, M. R., Price, D. L., & Geyer, M. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.023 · Cited by 6
Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method
Ray, T. S. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.12.018 · Cited by 6
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective
Marazziti, D., Weiss, F., Gurrieri, R., Russomanno, G., Gambini, M., Magnesa, A., Coccoglioniti, A., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2445016 · Cited by 5
Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA (‘Ecstasy’) Substance Use Disorder
Schenk, S., & Aronsen, D. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_421 · Cited by 4
Contractile effects of 3,4-methylenedioxymethamphetamine on the human internal mammary artery
Silva, S., Carvalho, F. D., Fernandes, E. G. R., Antunes, M. J., & Cotrim, M. D. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.04.002 · Cited by 5
Hyperthermia Severely Affects the Vascular Effects of MDMA and Metabolites in the Human Internal Mammary Artery In Vitro
Fonseca, D. A., Guerra, A. F. D. C. T., Carvalho, F. D., Fernandes, E. G. R., Ferreira, L. M., Branco, P. S., Antunes, P. E., Antunes, M. J., & Cotrim, M. D. (2017) · Cardiovascular Toxicology · doi:10.1007/s12012-017-9398-y · Cited by 5
Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.
Tao, R., Shokry, I. M., & Callanan, J. J. (2017) · PubMed · Cited by 5
Psychedelic therapeutics in psychiatric conditions
Harvey, P. D., & Nemeroff, C. B. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02335-z · Cited by 5
History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
Casey, A. B., & Heifets, B. D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70225 · Cited by 4
The psychedelic-peptide paradox: a hormetic hypothesis
Carter, C. S. (2025) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2025.100303 · Cited by 4
Ketanserin reduces the postischemic EEG and behavioural changes following Endothelin-1-induced occlusion of the middle cerebral artery in conscious rats
Moyanova, S. G., Kortenska, L., Kirov, R., Itzev, D. E., & Usunoff, K. G. (2008) · Open Medicine · doi:10.2478/s11536-008-0058-2 · Cited by 4
Serotonin and serotonin receptors in hallucinogen action
Halberstadt, A. L., & Nichols, D. E. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00043-8 · Cited by 4
Psychopharmacology of MDMA (Ecstasy)
Gold, M. S., Tabrah, H., & Frost-Pineda, K. (2001) · Psychiatric Annals · doi:10.3928/0048-5713-20011101-09 · Cited by 4
A dual-receptor model of serotonergic psychedelicsPreprint
Juliani, A., Chelu, V., Graesser, L., & Safron, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.12.589282 · Cited by 4
Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use
Ramaekers, J. G., Kuypers, K. P. C., & Vollenweider, F. X. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03602-7 · Cited by 3
La psychothérapie assistée par la MDMA dans la prise en charge du syndrome de stress post-traumatique
Fauvel, B., & Piolino, P. (2021) · Psychologie Française · doi:10.1016/j.psfr.2020.12.003 · Cited by 4
A brain imaging study of dopamine receptor D2 availability in cannabis dependent users after recovery from cannabis-induced psychosis
Weinstein, A. M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1230760 · Cited by 4
Methylenedioxymethamphetamine (Ecstasy, MDMA)
Buckley, N. A. (2012) · Wiley eBooks · doi:10.1002/9781118105955.ch9 · Cited by 3
Pharmacological profiling of novel psychoactive substances
Liechti, M. E., Simmler, L. D., Sitte, H. H., & Luethi, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818788-3.00003-6 · Cited by 2
Self-citation
The Psychopharmacology of Hallucinations: Ironic Insights into Mechanisms of Action
Lowe, N. G., Rapagnani, M. P., Mattei, C., & Stahl, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4121-2_24 · Cited by 3
A Clinical Crossroads for MDMA
Guillot, C. R. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399818 · Cited by 2
The Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3

Authors: Liechti, M.
Affiliations: Psychiatrische Universitätsklinik Zürich (CH)
Corresponding author: Liechti, M
ORCID: Liechti, M
Venue: Neuropsychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 2000-10
Volume: 23
Issue: 4
Pages: 396-404
ISSN: 0893-133X (ISSN-L)
DOI: 10.1016/s0893-133x(00)00126-3
OpenAlex: W2137229007
Cited by: 245
References: 34
Citations by year: 2026: 7 · 2025: 6 · 2024: 15 · 2023: 9 · 2022: 10 · 2021: 10 · 2020: 7 · 2019: 5 · 2018: 12 · 2017: 14 · 2016: 8 · 2015: 9 · 2014: 13 · 2013: 5 · 2012: 13
FWCI: 10.33
Type: journal article
Language: en
Open access: closed
Locations: Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Heffter Research Institute
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords: MDMA, ecstasy, ketanserin, 5-HT2 receptor antagonism, serotonin, subjective effects, perceptual change, emotional arousal, body temperature, blood pressure, heart rate, adverse effects, drug interactions
MeSH terms: Adult, Affect, Analysis of Variance, Blood Pressure, Body Temperature, Double-Blind Method, Female, Hallucinations, Hallucinogens, Heart Rate, Humans, Ketanserin, Male, Perception, Psychometrics, Receptors, Serotonin, Serotonin Antagonists, Serotonin Agents, Statistics, Nonparametric, N-Methyl-3,4-methylenedioxyamphetamine, Receptor, Serotonin, 5-HT2A, Receptor, Serotonin, 5-HT2C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks